Hospitalisations with infections related to antimicrobial-resistant bacteria from the French nationwide hospital discharge database, 2016.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
01 2019
Historique:
entrez: 15 3 2019
pubmed: 15 3 2019
medline: 25 3 2020
Statut: ppublish

Résumé

Massive use of antibiotics has led to increased bacterial resistance to these drugs, making infections more difficult to treat. Few studies have assessed the overall antimicrobial resistance (AMR) burden, and there is a paucity of comprehensive data to inform health policies. This study aims to assess the overall annual incident number of hospitalised patients with AMR infection in France, using the National Hospital Discharge database. All incident hospitalisations with acute infections in 2016 were extracted. Infections which could be linked with an infecting microorganism were first analysed. Then, an extrapolation of bacterial species and resistance status was performed, according to age class, gender and infection site to estimate the total number of AMR cases. Resistant bacteria caused 139 105 (95% CI 127 920-150 289) infections, resulting in a 12.3% (95% CI 11.3-13.2) resistance rate. ESBL-producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus were the most common resistant bacteria (>50%), causing respectively 49 692 (95% CI 47 223-52 142) and 19 493 (95% CI 15 237-23 747) infections. Although assumptions are needed to provide national estimates, information from PMSI is comprehensive, covering all acute bacterial infections and a wide variety of microorganisms.

Identifiants

pubmed: 30869047
pii: S0950268819000402
doi: 10.1017/S0950268819000402
pmc: PMC6518510
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e144

Références

Emerg Infect Dis. 2004 Mar;10(3):514-7
pubmed: 15109426
Microbiol Mol Biol Rev. 2010 Sep;74(3):417-33
pubmed: 20805405
Environ Health Perspect. 2012 Aug;120(8):1100-6
pubmed: 22571927
Pediatrics. 2014 Feb;133(2):e322-9
pubmed: 24420803
Med Arch. 2013;67(5):329-32
pubmed: 24601163
Pediatr Infect Dis J. 2014 Sep;33(9):929-32
pubmed: 24642515
Infect Control Hosp Epidemiol. 2014 Jun;35(6):646-51
pubmed: 24799640
Lancet Infect Dis. 2014 Aug;14(8):742-750
pubmed: 25022435
Autoimmun Rev. 2014 Nov;13(11):1082-9
pubmed: 25172239
Med Mal Infect. 2014 Dec;44(11-12):509-14
pubmed: 25455077
Clin Microbiol Infect. 2016 May;22(5):416-22
pubmed: 26706614
J Antimicrob Chemother. 2016 Jun;71(6):1564-9
pubmed: 26892779
Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):785-9
pubmed: 27125251
PLoS Med. 2016 Nov 29;13(11):e1002184
pubmed: 27898664
Antimicrob Resist Infect Control. 2016 Dec 12;5:56
pubmed: 27999665
BMC Infect Dis. 2017 Apr 17;17(1):279
pubmed: 28415969
J Neurol. 2017 Jun;264(6):1185-1192
pubmed: 28516332
Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):57-63
pubmed: 28648494
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
Fundam Clin Pharmacol. 2018 Feb;32(1):108-113
pubmed: 29055145
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Lancet Glob Health. 2018 Sep;6(9):e969-e979
pubmed: 30103998
Lancet Infect Dis. 2019 Jan;19(1):56-66
pubmed: 30409683
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716

Auteurs

M Opatowski (M)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

P Tuppin (P)

Caisse nationale de l'assurance maladie, Direction de la stratégie des études et des statistiques,Paris,France.

K Cosker (K)

Département Biostatistiques, Santé Publique, Information médicale, AP-HP Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix,Paris,France.

M Touat (M)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

G De Lagasnerie (G)

Laboratoire Interdisciplinaire d'évaluation des Politiques Publiques,Paris,France.

D Guillemot (D)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

J Salomon (J)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

C Brun-Buisson (C)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

L Watier (L)

Biostatistics, Biomathematics, Pharmacoepidemiology and Infectious Diseases (B2PHI), Inserm, UVSQ, Institut Pasteur, Université Paris-Saclay,Paris,France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH